Moderna launches clinical trials of HIV vaccine

It turns out that pharmaceutical company Moderna will begin clinical trials

This was made clear by the publication of clinical trial schedules in the National Institutes of Health database. According to the information, 56 people aged 18 to 50 years who are HIV-negative are the subjects of the clinical trial. It will start on Thursday, August 19, 2021 and will end in the spring of 2023.

In January 2021, Moderna announced the development of vaccines for the HIV virus, influenza virus, and Nipah virus.

The HIV vaccine has already cleared Phase I trials to confirm the safety of a small number of people in early 2021, and in the future, Phase II trials to confirm the overall efficacy of the vaccine, 'PreP' A phase III study will be conducted to verify the efficacy compared to other prophylactic treatments such as pre-exposure prophylaxis called pre-exposure prophylaxis.

According to the news site them., The RNA vaccine technology itself has existed for decades, but the number was limited due to the time-consuming approval of the US Food and Drug Administration (FDA). .. However, the situation has changed completely due to the acceleration of clinical trials and the FDA's approval schedule due to the public-private partnership program ' Operation Warp Speed' based on the pandemic of the new coronavirus infection.

It is expected that mRNA vaccines can be produced that are suitable for malaria for which no previously approved vaccine has existed.

Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice | npj Vaccines
https://doi.org/10.1038/s41541-021-00345-0